Physician profile
Christopher D Cain
NPI 1598236325
$337.45
in general payments reported to CMS, 2019-2025
12 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $33.61 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $337.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $68.91 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Alkermes, INC. | $39.56 | 2025 | Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.58 | 2025 | Caplyta |
| Lilly USA, LLC | $36.31 | 2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $36.30 | 2025 | Ozempic, Wegovy |
| Abbvie INC. | $19.60 | 2025 | |
| Gilead Sciences, INC. | $19.58 | 2025 | |
| Merck Sharp & Dohme LLC | $19.00 | 2023 | Dificid, Pifeltro, Delstrigo |
| Astrazeneca Pharmaceuticals LP | $16.46 | 2025 | Breztri |
| Pfizer INC. | $14.62 | 2025 | |
| Viiv Healthcare Company | $14.61 | 2023 | Dovato |
| Glaxosmithkline, LLC. | $13.92 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.